Clinicogenetic risk modeling in ATL.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.Viruses · 2022
   Review
2. Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas.Diagnostics (Basel, Switzerland) · 2022
   Review
3. Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach.International journal of molecular sciences · 2022
   Review
4. Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets.Cancers · 2021
   Review
5. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.Blood · 2020
   Article

Corrections and comments

• Comment on
  Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as